T. Behle

Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

C. Landersdorfer, Jian Li, R. Nation, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii 2

T. Behle, A. Zavascki, N. T. Lopes, 2015 .

Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.

M. Nunes, D. Falci, T. Behle, 2015, The Journal of antimicrobial chemotherapy.

Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study.

T. Behle, A. Zavascki, V. Ribeiro, 2014, The Journal of antimicrobial chemotherapy.

Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections

T. Behle, A. Zavascki, N. T. Lopes, 2015, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

C. Landersdorfer, J. Li, R. Nation, 2013, The Journal of antimicrobial chemotherapy.

Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections

T. Behle, A. Zavascki, N. T. Lopes, 2015, Antimicrobial Agents and Chemotherapy.